Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.
- DOI
- 10.1002/cpt.1712
- Published
- 2020 May
- Container
- Clinical pharmacology and therapeutics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cpt.1712,
title = {Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.},
author = {Biemans VBC and van der Woude CJ and Dijkstra G and van der Meulen-de Jong AE and Oldenburg B and de Boer NK and Löwenberg M and Srivastava N and Bodelier AGL and West RL and Jansen JM and de Vries AC and Haans JJL and de Jong DJ and Pierik MJ and Hoentjen F},
year = {2020},
journal = {Clinical pharmacology and therapeutics},
doi = {10.1002/cpt.1712},
url = {https://doi.org/10.1002/cpt.1712}
}RIS
TY - JOUR TI - Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. AU - Biemans VBC AU - van der Woude CJ AU - Dijkstra G AU - van der Meulen-de Jong AE AU - Oldenburg B AU - de Boer NK AU - Löwenberg M AU - Srivastava N AU - Bodelier AGL AU - West RL AU - Jansen JM AU - de Vries AC AU - Haans JJL AU - de Jong DJ AU - Pierik MJ AU - Hoentjen F PY - 2020 JO - Clinical pharmacology and therapeutics DO - 10.1002/cpt.1712 UR - https://doi.org/10.1002/cpt.1712 ER -
APA
VBC, B., CJ, V. D. W., G, D., AE, V. D. M. J., B, O., NK, D. B., M, L., N, S., AGL, B., RL, W., JM, J., AC, D. V., JJL, H., DJ, D. J., MJ, P., & F, H. (2020). Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.. Clinical pharmacology and therapeutics. https://doi.org/10.1002/cpt.1712
Source records
- pubmed · retrieved 2026-09-26T16:04:34.681Z